Login to Your Account



Pirfenidone Panel, Tracleer Data to Start IPF Pot Boiling

By Randy Osborne


Monday, February 8, 2010
As the clock ticks on top-line Phase III data from Actelion Ltd. with Tracleer (bosentan) in idiopathic pulmonary fibrosis, the FDA last week put InterMune Inc. on notice that an advisory panel in March will take up the case of its compound, pirfenidone, which stands a regulatory step ahead in the race to the IPF market.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription